Supplementary Figure 8: Effect of treatment with the EGFR kinase inhibitor erlotinib on RAF-MEK inhibitor sensitivity. | Nature Genetics

Supplementary Figure 8: Effect of treatment with the EGFR kinase inhibitor erlotinib on RAF-MEK inhibitor sensitivity.

From: The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies

Supplementary Figure 8

(a,b) Effect of treatment with the EGFR kinase inhibitor erlotinib on (a) vemurafenib and (b) trametinib sensitivity in A2058 BRAF V600E–mutant melanoma cells. (c,d) Effect of EGFR kinase inhibitor erlotinib on (c) vemurafenib and (d) trametinib sensitivity in KHM-5M BRAF V600E–mutant thyroid cancer cells.

Back to article page